Please login to the form below

Not currently logged in

Bayer acquires rights to SciLin insulin

Bayer Schering Pharma has acquired to exclusive rights to market and distribute Bioton's SciLin insulin in China

Bayer Schering Pharma has acquired to exclusive rights to market and distribute Bioton's SciLin insulin in China.

The deal involves an up-front payment of €31m to the Polish insulin producer and will guarantee a secured supply of the insulin product for the next 15 years for exclusive commercial delivery by Bayer in the Chinese market.

Janusz R Guy, CEO of Bioton said: "With this agreement for long-term collaboration, Bioton has [realised] one of its strategic goals to develop its strong international position on growing insulin markets via alliances with leading pharmaceutical companies."

There are around 40 million diabetes sufferers in China and insulin has a projected annual growth rate of more than 40 per cent.

"Today, Bayer is already a top ranking international pharmaceutical company in China with our pharmaceutical Glucobay for treatment of type 2 diabetes being the most successful product. Through the planned distribution of SciLin, we will further supply patients suffering from diabetes, and will expand our position in this very promising growth market," said Andreas Fibig, CEO of Bayer Schering Pharma.

9th July 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...